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Aging

Ophthalmology

Macrophage aging is pathogenic in diseases of the elderly, including age-related macular
degeneration (AMD), a leading cause of blindness in older adults. However, the role of
microRNAs, which modulate immune processes, in regulating macrophage dysfunction and
thereby promoting age-associated diseases is underexplored. Here, we report that
microRNA-150 (miR-150) coordinates transcriptomic changes in aged murine
macrophages, especially those associated with aberrant lipid trafficking and metabolism in
AMD pathogenesis. Molecular profiling confirmed that aged murine macrophages exhibit
dysregulated ceramide and phospholipid profiles compared with young macrophages. Of
translational relevance, upregulation of miR-150 in human peripheral blood mononuclear
cells was also significantly associated with increased odds of AMD, even after controlling
for age. Mechanistically, miR-150 directly targets stearoyl-CoA desaturase-2, which
coordinates macrophage-mediated inflammation and pathologic angiogenesis, as seen in
AMD, in a VEGF-independent manner. Together, our results implicate miR-150 as
pathogenic in AMD and provide potentially novel molecular insights into diseases of aging.
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Macrophage aging is pathogenic in diseases of the elderly, including age-related macular
degeneration (AMD), a leading cause of blindness in older adults. However, the role of microRNAs,
which modulate immune processes, in regulating macrophage dysfunction and thereby promoting
age-associated diseases is underexplored. Here, we report that microRNA-150 (miR-150)
coordinates transcriptomic changes in aged murine macrophages, especially those associated with
aberrant lipid trafficking and metabolism in AMD pathogenesis. Molecular profiling confirmed
that aged murine macrophages exhibit dysregulated ceramide and phospholipid profiles compared
with young macrophages. Of translational relevance, upregulation of miR-150 in human peripheral
blood mononuclear cells was also significantly associated with increased odds of AMD, even after
controlling for age. Mechanistically, miR-150 directly targets stearoyl-CoA desaturase-2, which
coordinates macrophage-mediated inflammation and pathologic angiogenesis, as seen in AMD, in
a VEGF-independent manner. Together, our results implicate miR-150 as pathogenic in AMD and
provide potentially novel molecular insights into diseases of aging.
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Macrophages are critical effector cells of the innate immune system. Multiple groups, including our own,
have reported that macrophages from aged mice demonstrate a functional drift compared with those isolated
from young mice. For example, aged macrophages exhibit epigenomic changes, leading to reduced autophagic capacity (1), and are defective in their ability to fight viral infections due to reduced phagocytic activity (2).
Moreover, aged macrophages are skewed toward a proangiogenic gene and cytokine expression profile, which
leads to dysregulated inflammation and the inability to inhibit pathological angiogenesis (3). Aged macrophages also exhibit impaired cholesterol efflux due to decreased Abca1 expression, leading to intracellular
cholesterol accumulation and pathologic vascular proliferation (4). Age-associated macrophage dysfunction
has been proposed to contribute to the pathogenesis of numerous diseases of aging, including age-related
macular degeneration (AMD) and atherosclerosis (5). In addition, age-associated changes in microglia, the
major resident immune cell in the retina with similar phagocytic functions, may also promote AMD (6).
AMD is a leading cause of blindness in industrialized nations (7) and displays a complex disease
course characterized, initially, by accumulation of cholesterol-rich deposits known as drusen underneath
the retina (5, 8). Though drusen themselves do not typically cause vision loss, they are risk factors for
progression to one of 2 forms of advanced AMD: advanced neovascular (wet) AMD, characterized by
pathologic subretinal angiogenesis, or advanced dry AMD, characterized by geographic atrophy secondary to loss of retinal neurons and underlying cells. Both forms of advanced AMD can cause debilitating
blindness, though wet AMD causes a significant portion of the vision loss associated with AMD (9). While
anti-VEGF therapies have revolutionized treatment options for wet AMD, an important subset of patients
is un- or underresponsive to this therapy (8). Of interest, genome-wide association studies show that polymorphisms in lipid-related genes, including hepatic lipase (LIPC), ATP-binding cassette transporter member 1 (ABCA1), and cholesterol ester transfer protein (CETP), are associated with advanced AMD (10),
supporting the idea that impaired cholesterol homeostasis contributes to AMD pathogenesis.

insight.jci.org   https://doi.org/10.1172/jci.insight.120157
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Impaired cholesterol homeostasis also contributes to the pathogenesis of atherosclerosis. Atherosclerotic plaque formation begins when circulating monocytes adhere to the vascular endothelium, migrate to
the sub-endothelial space, and activate into macrophages that take up lipids and become foam cells (11,
12). Past studies have demonstrated that the activation/polarization state of macrophages is important for
predicting plaque phenotype and stability (13, 14). For example, in patients with hypercholesterolemia,
macrophages polarize to a more proinflammatory state, which could predispose to plaque formation (15).
Moreover, macrophage cholesterol efflux capacity in human patients is a clinically relevant predictor of
atherosclerotic coronary artery disease (16), suggesting that perturbations in cholesterol homeostasis promote disease. Remarkably, atherosclerotic plaques and drusen have similar lipid compositions (17–20), unifying the pathogenic pathways underlying these diseases. Based on these similarities, some have proposed
that it may be possible to repurpose statins, lipid-lowering drugs used to treat atherosclerosis, for treating
AMD (21, 22), although not all studies have yielded these same conclusions (23).
Despite these advances in our understanding of the phenotype of aged macrophages and how such
changes contribute to age-associated diseases, the molecular mechanisms by which macrophages drift
toward the disease-promoting phenotype remain elusive. Given the immense spectrum of these changes
in aged macrophages, we hypothesized that microRNAs (miRs) may regulate the transcriptome of macrophages and, thereby, the transition of macrophages to a disease-promoting phenotype. The ability of miRs
to target multiple genes makes them strong candidates as molecular regulators that skew macrophages
toward a disease-promoting phenotype. Previous studies have examined the miR signatures of AMD by
profiling eye fluids, such as human vitreous humor and plasma, providing phenotypic characterization, but
they have failed to provide mechanistic insights into the underlying disease etiology (24, 25). Therefore,
further elucidation of the target genes of these miRs, the affected cell types, and the molecular pathways
involved is necessary for a more complete understanding of disease pathogenesis.
In this study, we sought to identify one or more miRs that regulate the disease-promoting programmatic changes in macrophages that are associated with AMD. Our results demonstrate that miR-150 is highly
upregulated both in disease-promoting murine macrophages and in human peripheral blood mononuclear cells
(PBMCs) from AMD patients. Moreover, we show that miR-150 regulates macrophage-mediated inflammation
and pathologic angiogenesis independently from VEGF by targeting stearoyl-CoA desaturase-2 (Scd2), suggesting that it regulates the transition of macrophages from a healthy profile to the AMD-promoting phenotype. Ultimately, these findings provide insight into the mechanisms underlying the pathological programmatic changes
in aged macrophages and may lead to the identification of novel therapeutic targets and candidate biomarkers.

Results
Aged macrophages have distinct cholesterol-responsive miR networks. Since miRs can regulate numerous target
genes, we hypothesized that miRs may globally regulate the macrophage’s response to exogenous cholesterol. We first sought to identify cholesterol-responsive miRs by performing a microarray, comparing untreated macrophages versus macrophages treated with acetylated LDL (acLDL) or oxidized LDL (oxLDL). We
previously showed that aged and young macrophages handle cholesterol differently and that aged macrophages demonstrate altered capacity to metabolize cholesterol (4). As such, we profiled aged and young
macrophages separately to accurately capture the response of these cells to exogenous cholesterol. In young
macrophages, 10 miRs were similarly downregulated in response to both acLDL and oxLDL (Figure 1A).
In contrast, in aged macrophages, 5 miRs were similarly dysregulated in response to both acLDL and
oxLDL: 3 downregulated and 2 upregulated (Figure 1B). These findings suggest that, in macrophages,
miRs are altered after exposure to cholesterol and may indeed orchestrate the macrophage’s response to
cholesterol. Furthermore, these findings suggest that the distinct miR responses in aged versus young macrophages may underlie their distinct responses to exogenous cholesterol.
In addition to these cholesterol-responsive miRs, we hypothesized that there may be a separate network of miRs that regulate the broad spectrum of differences between disease-promoting, aged macrophages and young macrophages. Such a miR must not only demonstrate altered expression with aging,
but must also have consistent dysregulation regardless of treatment with cholesterol. Five miRs were
upregulated in aged macrophages and maintained the same pattern of dysregulation in aged versus
young macrophages after treatment with acLDL or oxLDL (Figure 1C). miR-150 was the strongest
candidate for further study, given that it had the highest fold change in aged versus young macrophages
and since the others did not validate after further characterization.
insight.jci.org   https://doi.org/10.1172/jci.insight.120157
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Figure 1. microRNA-150 is upregulated in aged macrophages of diverse origins. (A) In young macrophages, 10 microRNAs were downregulated similarly in
response to acetylated low-density lipoprotein (acLDL) and oxidized low-density lipoprotein (oxLDL). (B) In aged macrophages, 5 microRNAs were dysregulated similarly in response to acLDL and oxLDL. (C) In untreated (UT), acLDL-treated, and oxLDL-treated macrophages, 5 microRNAs were dysregulated similarly in aged and young macrophages under the same treatment conditions. microRNA-150 was upregulated in aged peritoneal macrophages (PM) (D; n = 12/
group; 2-tailed Mann-Whitney U test), aged splenic macrophages (SM) (E; n = 13/group; 2-tailed Mann-Whitney U test), and aged BM-derived macrophages
(BMDM) (F; n = 10/group; 2-tailed, unpaired Welch’s t test). (G) Upregulation of microRNA-150 in aged PMs was not affected by treatment with acLDL (n
= 7/group; 2-tailed Mann-Whitney U test), oxLDL (n = 7/group; 2-tailed, unpaired Welch’s t test), or LPS (n = 5/group; 2-tailed Mann-Whitney U test). (H)
Upregulation of microRNA-150 in aged BMDMs was not affected by treatment with oxLDL (n = 5/group; 2-tailed Mann-Whitney U test) or LPS (n = 5/group;
2-tailed Mann-Whitney U test). Open circles depict individual data points; graphs depict mean ± SEM (A–F) (*P < 0.05; **P < 0.01; ****P < 0.0001).

miR-150 is upregulated in aged macrophages of diverse origins. To validate the microarray data, we
performed quantitative PCR (qPCR) with independent samples. Indeed, aged peritoneal macrophages
(PMs) had 9-fold increased miR-150 expression at baseline compared with young PMs (Figure 1D).
To determine whether this phenomenon was lineage specific, we also measured miR-150 expression
in splenic macrophages (SMs) and BM-derived macrophages (BMDMs). Similar to PMs, we found
that aged SMs (Figure 1E) and BMDMs (Figure 1F) exhibited 3-fold higher expression of miR-150 at
baseline compared with young SMs and BMDMs. Next, we sought to confirm that miR-150 upregulation in aged macrophages is unaffected by exposure to exogenous cholesterol or LPS. Indeed, aged
PMs treated with acLDL, oxLDL, or LPS exhibited higher miR-150 expression than similarly treated
young PMs (Figure 1G). Likewise, oxLDL- and LPS-treated aged BMDMs also had higher miR-150
expression compared with similarly treated young BMDMs (Figure 1H). Cumulatively, these findings provide strong evidence that miR-150 upregulation may indeed skew macrophages toward the
disease-promoting, aged phenotype.
insight.jci.org   https://doi.org/10.1172/jci.insight.120157
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Figure 2. microRNA-150 (miR-150) regulates inflammation and lipid metabolism in macrophages. (A) RNA-sequencing followed by hierarchical clustering revealed clear transcriptomic differences between macrophages transfected with miR-150 mimic versus those transfected with a
nontargeting negative control. Pathway analysis of the dysregulated genes in miR-150–overexpressing macrophages that are also dysregulated in
aged macrophages (Jonathan B. Lin, unpublished observations) suggested perturbations in numerous gene ontology (GO) processes (B), process
networks (C), and pathway maps (D). The altered transcriptomic profile of miR-150–overexpressing macrophages suggested dysregulation of
numerous inflammation and immune response process networks (C; brown and purple, respectively) and aberrant lipid trafficking and metabolism
in age-related macular degeneration (D; purple).

miR-150 overexpression reprograms the macrophage transcriptome. We next sought to determine the mechanism by which miR-150 skews macrophages toward the aged phenotype. To elucidate the cellular processes
and pathways regulated by miR-150, we performed RNA sequencing (RNA-Seq) to identify the transcriptomic networks dysregulated under conditions of miR-150 overexpression, comparing young macrophages
transfected with miR-150–overexpressing mimic (miR-150OE) to young macrophages transfected with a
nontargeting negative control (NC) mimic. From RNA-Seq, we obtained an average of 35,607,314 reads
per sample (n = 11), and of these, an average of 32,535,035 reads (91.4%) mapped to the mouse genome
(Mus_musculus reference build Ensembl_R76). We performed hierarchical clustering, revealing clear differences between the transcriptomes of miR-150OE and NC-transfected PMs (Figure 2A).
insight.jci.org   https://doi.org/10.1172/jci.insight.120157
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Figure 3. Aged macrophages have altered ceramide and phospholipid profiles. (A) Aged macrophages contained significantly more long-chain C16:0 than
young macrophages but similar levels of very long-chain C22:0 and C24:0 (n = 5/group; 2-tailed, unpaired Welch’s t test), resulting in decreased C22:0/
C16:0 and C24:0/C16:0 ratios (B; n = 5/group; 2-tailed, unpaired Welch’s t test). Young and aged macrophages had similar phosphatidylglycerol-D16:0-18:1
(PG-D16:0-18:1) content (C; n = 5/group; 2-tailed, unpaired student’s t test). Aged macrophages had higher total phosphatidylcholine (PC) (D; n = 5/group;
2-tailed, unpaired student’s t test) and higher total phosphatidylethanolamine (PE) (E; n = 5/group; 2-tailed, unpaired student’s t test), but they had
similar total phosphatidylinositol (PI) (F; n = 5/group; 2-tailed, unpaired Welch’s t test) and similar total phosphatidylserine (PS) (G; n = 5/group; 2-tailed,
unpaired Welch’s t test). Analysis of individual species revealed an interaction between age and species identity with increased levels of certain species
but not others within each phospholipid class (H–K; n = 5/group; 2-way, repeated-measures ANOVA with Bonferroni post-hoc test). Open circles depict
individual data points; graphs depict mean ± SEM (A–G) (*P < 0.05; **P < 0.01; #P < 0.0001).
insight.jci.org   https://doi.org/10.1172/jci.insight.120157
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Table 1. Demographic and clinical characteristics of human subjects
Variable

Age, mean (SD)

Control

AMD

P value

64.57 (10.27)

75.48 (12.77)

<0.001A

36
27

20
23

0.282B

63
0
0

0
20
23

N/A

Sex, n

Male
Female
AMD status, n

No AMD
Early AMD
Advanced neovascular (wet) AMD

Significant by 2-tailed, unpaired Welch’s t test; BNonsignificant by χ2 test.

A

To determine the subset of these miR-150–regulated genes that are also dysregulated in aged macrophages, we overlaid the RNA-Seq results onto the results of a previous microarray that we performed
comparing aged versus young macrophages (Jonathan B. Lin, unpublished observations). The intersection
between these gene lists identifies genes dysregulated in aged murine macrophages that may be regulated by
miR-150 upregulation. We identified 160 commonly dysregulated genes with a |fold change| > 1.2 both
in miR-150OE versus NC-transfected macrophages and in aged versus young macrophages. To determine
whether these genes suggested abnormalities in specific pathways, which may provide insight into the mechanism by which miR-150 upregulation promotes age-associated disease, we performed pathway analysis
with MetaCore for enrichment by gene ontology (GO) processes, process networks, and pathway maps
(Figure 2, B–D). Numerous diverse GO processes were enriched for, indicating that miR-150 regulates broad
cellular pathways in macrophages (Figure 2B). Of interest, inflammation and immune response process
networks were 5 of the 9 most enriched process networks (Figure 2C). These findings confirm that there is
immune dysregulation in aged macrophages associated with miR-150 upregulation. Remarkably, aberrant
lipid trafficking and metabolism in AMD was the third most enriched pathway map (Figure 2D), validating
our hypothesis that miR-150 regulates the transition of macrophages to the AMD-promoting phenotype.
Disease-promoting macrophages have altered phospholipid and ceramide profiles. In AMD, the interaction
between dysregulated macrophage cholesterol homeostasis and aging is implicated in the pathophysiology
of disease. To better understand this relationship, we performed lipidomics to determine whether aged
macrophages have altered lipid profiles as possible consequences of aberrant lipid trafficking and metabolism. We focused on components of the plasma membrane, including ceramides and phospholipids, since
the composition and organization of the plasma membrane have been shown to regulate macrophage function (26). Aged macrophages contained significantly more long-chain ceramide (C16:0) than young macrophages but similar levels of very long–chain C22:0 and C24:0 (Figure 3A). Consistent with increased
C16:0, we observed a significant decrease in both the C22:0/C16:0 and C24:0/C16:0 ratios in aged versus
young macrophages (Figure 3B). These findings indicate that aged macrophages exhibit remodeling of
their ceramide composition from very long–chain to long-chain species.
In the phosphatidylglycerol (PG) class, PG-D16:0-18:1 was the only detectable species, and there
was no significant difference in content between aged and young macrophages (Figure 3C). However,
numerous individual species were detected for each of the other phospholipid classes. Overall, aged macrophages contained more total phosphatidylcholine (PC; Figure 3D) and more total phosphatidylethanolamine (PE; Figure 3E) than young macrophages but similar total phosphatidylinositol (PI; Figure 3F)
and similar total phosphatidylserine (PS; Figure 3G). Further analysis of the individual species within
each phospholipid class by 2-way, repeated-measures ANOVA revealed a significant interaction between
the main effects of species identity and age for all 4 phospholipid classes (Figure 3, H–K), indicating
that the increased total PC and total PE in aged macrophages were driven by increases in specific species
within these phospholipid classes. Post hoc testing showed that the significantly increased species were
generally phospholipids containing fatty acids with multiple double bonds, suggesting a shift toward
unsaturated fatty acids (Figure 3, H–K). Based on these findings, we propose that aberrant lipid trafficking and metabolism in aged macrophages leads to this disruption in ceramide and phospholipid profiles,
which may contribute to macrophage dysfunction in age-associated diseases.
insight.jci.org   https://doi.org/10.1172/jci.insight.120157
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Figure 4. Upregulation of microRNA-150 in human peripheral blood mononuclear cells (PBMCs) is associated with age-related macular degeneration
(AMD). (A) AMD patients (n = 43) had higher PBMC microRNA-150 copy numbers compared with controls (n = 63; 2-tailed Mann-Whitney U test). (B) Both
early AMD (n = 20) and wet AMD patients (n = 23) had higher PBMC microRNA-150 copy numbers compared with controls (n = 63), but there was no significant difference between early and wet AMD patients (Kruskal-Wallis test with Dunn’s multiple comparison post-hoc test). (C) There was no correlation
between PBMC microRNA-150 copy number and age in AMD patients or controls. Patients in the highest tertile of microRNA-150 copy number and above
median age, as indicated by the dashed rectangle, had the highest prevalence of AMD (87.5%). Open circles depict individual human subjects (A–C); horizontal lines depict medians (A and B) (**P < 0.01; ***P < 0.001; ****P < 0.0001).

miR-150 upregulation is associated with AMD in humans. To assess the translational relevance of these findings, we recruited human patients with early AMD or advanced neovascular (wet) AMD and non-AMD
controls in a case-control study design. Demographic and clinical information of the participants are shown
in Table 1. From these patients, we collected PBMCs, which contain mostly monocytes, and quantified
miR-150 copy number in these samples. On average, AMD patients had significantly higher PBMC miR-150
levels compared with control subjects (Figure 4A). When we subdivided AMD patients into early AMD and
wet AMD groups, we observed higher PBMC miR-150 levels in early AMD patients compared with controls
and in wet AMD patients compared with controls (Figure 4B). There was, however, no significant difference in
PBMC miR-150 levels between early and wet AMD patients (Figure 4B). These findings suggest that increased
PBMC miR-150 levels are associated with developing AMD but not with disease progression. We next sought
to determine whether age affected PBMC miR-150 levels, since AMD patients tended to be older than nonAMD controls (Table 1). We found that there was no significant correlation between age and PBMC miR-150
levels in AMD patients (rs = 0.1596, P = 0.3066) or in control subjects (rs = –0.2002, P = 0.1157) (Figure 4C),
suggesting that there is no significant association between PBMC miR-150 levels and age.
To model the relationship between PBMC miR-150 levels and AMD status and to rigorously control for a
possible — albeit unlikely — effect of age, we generated a binary logistic regression model with the predictor
variables of age, sex, and log10-transformed PBMC miR-150 levels and the outcome of AMD. The overall model
was statistically significant (LR χ2 = 47.4, degrees of freedom [df] = 3, P < 0.001) and had good fit (χ2 = 9.4, df
= 8, P = 0.311). As expected, age was a significant predictor of AMD (P < 0.001) with a β coefficient of 0.082,
indicating that each additional year of age was associated with increased odds of having AMD (adjusted odds
ratio [aOR] = 1.086; 95% CI, 1.04–1.13). Of significant interest, even after controlling for the effects of age and
sex on miR-150 levels, log10-transformed PBMC miR-150 levels were highly associated with AMD (P < 0.001)
with a β coefficient of 3.367, indicating that each additional 10-fold increase in PBMC miR-150 levels was associated with 29.0-fold increased odds of having AMD (95% CI, 5.9–141.5). To determine the efficacy of PBMC
miR-150 levels as a potential marker of AMD, we generated a receiver operating characteristic (ROC) curve
and found that the area under the ROC curve was 0.860 (95% CI, 0.788–0.933), indicating good discrimination.
Furthermore, we performed conjunctive analysis to illustrate the relationship between PBMC miR-150
levels, age, and the outcome of AMD. We divided patients into tertiles by PBMC miR-150 levels (cutoffs
of 4.5 × 106 and 9.5 × 106 copies/ng RNA) and by age (i.e., above versus below a median of 67.47 years),
tabulating the AMD prevalence in each conjoined cell (Table 2). This analysis demonstrated a clear stepwise increase in prevalence of AMD going from the lowest to the highest tertile of PBMC miR-150 levels in
participants both above median age (i.e., from 18.8% to 53.8% to 87.5%) and below median age (i.e., from
15.8% to 17.4% to 45.5%). These findings strongly support the notion that increased PBMC miR-150 levels
are associated with AMD. This trend held true both above and below median age, making it highly unlikely
that the differences in PBMC miR-150 levels in AMD patients versus non-AMD controls were solely due
to the fact that the AMD patients were, on average, older.
insight.jci.org   https://doi.org/10.1172/jci.insight.120157

7

RESEARCH ARTICLE

Table 2. Age-related macular degeneration as a function of age and peripheral blood mononuclear cell (PBMC) microRNA-150
(miR-150) levels
Age

PBMC miR-150

Lowest tertile
Middle tertile
Highest tertile
Total

Below median
3/19 (15.8%)
4/23 (17.4%)
5/11 (45.5%)
12/53 (22.6%)

Above median
3/16 (18.8%)
7/13 (53.8%)
21/24 (87.5%)
31/53 (58.5%)

Total
6/35 (17.1%)
11/36 (30.6%)
26/35 (74.3%)
43/106 (40.6%)

miR-150 directly targets Scd2 and promotes pathologic angiogenesis. To understand the mechanism by which
miR-150 promotes macrophage dysfunction, we sought to identify direct miR-150 targets. Since miRs
canonically downregulate their gene targets, we filtered for commonly downregulated genes (fold change
< –1.2) both in miR-150OE and NC-transfected macrophages and in aged versus young macrophages. This
strategy identified 36 initial putative target genes (Supplemental Table 1; supplemental material available
online with this article; https://doi.org/10.1172/jci.insight.120157DS1). We further narrowed this list by
eliminating genes that either did not appear in any of 6 target identification databases or did not contain a
seed sequence in their 3′ UTR. We performed qPCR in aged versus young macrophages on the remaining
26 genes. Of these 26 genes, 8 showed significant downregulation in aged macrophages (Figure 5, A and
B). Of interest, 2 of the 8 genes that were significantly downregulated in aged macrophages are known to
play key roles in fatty acid biosynthesis: fatty acid synthase (Fasn) and Scd2. We confirmed that both genes
were indeed downregulated in miR-150OE macrophages versus NC-transfected macrophages (Figure 5, C
and D). To determine the functional effect of Fasn and Scd2 deficiency, we performed siRNA knockdown of
these gene targets in macrophages and assessed the inflammation status and angiogenic potential of these
macrophages by PCR array. We confirmed siRNA knockdown of Fasn and Scd2 by qPCR (Figure 5, E and
F). Fasn-deficient macrophages exhibited upregulation of only Ptgs2 and Tnf (Figure 5G) and no upregulation of proangiogenic factors (Figure 5H). On the other hand, Scd2-deficient macrophages were abnormally
activated, with upregulation of numerous proinflammatory markers (Figure 5I) and proangiogenic factors
(Figure 5J). Of interest, Vegfa expression was not altered (Figure 5J), suggesting that Scd2-mediated regulation of macrophage function is independent from VEGF. These results suggest that Scd2 may be an important direct target of miR-150, providing a mechanism by which miR-150 regulates macrophage function.
Next, we performed dual-reporter assays to confirm that miR-150 can directly regulate Scd2 expression.
The Scd2 gene contains 2 canonical miR-150 seed sequence target sites in its 3′ UTR: a 7mer-A1 (3′ - UGGGAGA - 5′) and an offset 6mer (3′ - UUGGGA - 5′) (Figure 6A). As expected, cotransfection of a plasmid
with the Scd2 3′ UTR cloned downstream of a secreted Gaussia luciferase (GLuc) and miR-150 mimic led
to decreased GLuc activity compared with cotransfection of the same plasmid with a nontargeting mimic
(Figure 6B). Removing the 7mer-A1 target site (mutant 1) significantly reduced the extent to which miR150 cotransfection reduced GLuc activity (Figure 6C). In contrast, removing the offset 6mer target site
(mutant 2) did not change the negative regulatory effect of miR-150 cotransfection on GLuc activity (Figure 6C). These findings suggest that the 7mer-A1 site is the dominant target site to which miR-150 binds to
regulate Scd2 expression, while the offset 6mer site plays a less important role.
To determine whether downregulation of Scd2 may promote pathological angiogenesis, as seen in wet
AMD, we measured the extent to which Scd2-deficient macrophages inhibited choroidal neovascularization
(CNV) in a well-established murine model of injury-induced angiogenesis in the eye. Although host macrophages play an important role in regulating CNV, we have previously demonstrated that intravitreal injection of functional macrophages can augment the antiangiogenic effect (27). Therefore, we performed laser
injury to induce CNV and injected Scd2-deficient or NC-transfected macrophages intravitreally by adoptive
transfer immediately after injury. Adoptively transferred Scd2-deficient macrophages were not able to inhibit CNV as effectively as NC-transfected macrophages (Figure 6, D and E). This phenomenon was independent of VEGF since VEGF mRNA expression and protein secretion was not increased in Scd2-deficient
macrophages (Figure 5H and Figure 6F). To confirm these in vivo results, we also generated mice lacking
Scd2 in myelomonocytic cells, including macrophages, with the Cre-lox system (Scd2–m/–m). In agreement
insight.jci.org   https://doi.org/10.1172/jci.insight.120157
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Figure 5. microRNA-150 modulates fatty acid synthase (Fasn) and stearoyl-CoA desaturase-2 (Scd2) expression. (A and B) Eight of the 26 putative microRNA-150 targets had decreased expression in aged macrophages (n = 6-12/group; 2-tailed, unpaired Welch’s t test). (C and D) microRNA-150 mimic–transfected macrophages had reduced expression of Fasn and Scd2 compared with nontargeting negative control-transfected
(NC-transfected) macrophages (n = 12/group; 2-tailed, unpaired student’s t test). (E and F) Macrophages transfected with Fasn- and Scd2-targeting
small-interfering RNA (siRNA) had reduced expression of target genes (n = 4-5/group; 2-tailed, unpaired student’s t test; KD, knock down). (G and
H) Fasn-deficient (FasnKD) macrophages were somewhat abnormally activated but had normal expression of proangiogenic factors (n = 14/group;
2-tailed, unpaired Welch’s t test). (I and J) Scd2-deficient (Scd2KD) macrophages were abnormally activated and had increased expression of proangiogenic factors (n = 10/group; 2-tailed, unpaired Welch’s t test). Open circles depict individual data points; graphs depict mean ± SEM (C–F) (*P <
0.05; **P < 0.01; ***P < 0.001; #P < 0.0001).

with our adoptive transfer experiments, Scd2–m/–m mice had larger CNV complexes after laser injury compared with floxed controls (Scd2f/f) (Figure 6, G and H). In contrast, mice lacking Fasn in myelomonocytic
cells (Fasn–m/–m) and floxed controls (Fasnf/f) had similar CNV complex sizes after laser injury (Figure 6, I
and J). These findings confirm that Scd2 plays an important role in regulating macrophage function in the
context of pathological angiogenesis.
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Figure 6. microRNA-150 directly targets Scd2 and thereby promotes pathological angiogenesis. (A) The 3′ untranslated region (UTR) of Scd2 contains canonical 7mer-A1 and offset 6mer microRNA-150 binding sites. (B) Cotransfection of a dual-reporter plasmid with the Scd2 3′ UTR inserted
downstream of a secreted Gaussia luciferase (GLuc) reporter gene and microRNA-150 mimic led to reduced GLuc activity compared with cotransfection of the same plasmid with a negative control (NC) mimic (n = 10/group; 2-tailed, unpaired student’s t test). (C) Removing the 7mer-A1 target site
(mutant 1) but not the offset 6mer target site (mutant 2) reduced the extent to which microRNA-150 cotransfection inhibited GLuc activity (n = 10/
group; Kruskal-Wallis test with Dunn’s multiple comparison post-hoc test). (D and E) Adoptively transferred Scd2-deficient (Scd2KD) macrophages
were less able to inhibit laser injury–induced choroidal neovascularization (CNV) compared with NC-transfected macrophages (D, representative
images from n = 8–11 burns/group; 2-tailed, unpaired Welch’s t test). (F) In vitro VEGF secretion was not significantly increased in Scd2-deficient
macrophages (n = 16/group; 2-tailed, unpaired Welch’s t test). (G and H) Scd2–m/–m mice exhibited larger CNV complexes after laser injury compared
with Scd2f/f mice (G, representative images from n = 8–9 burns/group; 2-tailed Mann-Whitney U test). (I and J) Fasn–m/–m and Fasnf/f mice had similarly
sized CNV complexes after laser injury (I, representative images from n = 8 burns/group; 2-tailed Mann-Whitney U test). Scale bars: 100 μm (D, G, I).
Open circles depict individual data points; graphs depict mean ± SEM (B, E, F, H, J) (*P < 0.05; ***P < 0.001).
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Figure 7. Upregulation of miR-150 in aged macrophages causes stearoyl-CoA desaturase-2 deficiency and dysregulated lipid metabolism, thereby promoting pathological angiogenesis, as seen in age-related macular degeneration.

Together, these findings indicate that Scd2 downregulation secondary to miR-150 upregulation in aged
macrophages promotes macrophage dysfunction and pathological angiogenesis, providing a mechanism by
which miR-150 can direct macrophages toward an aged, disease-promoting, and proangiogenic phenotype
(Figure 7). Our human data confirm the translational relevance of these findings in AMD pathogenesis.

Discussion
In this study, we report that miR-150 is upregulated in aged murine macrophages of diverse origins and
directs aged macrophages toward a disease-promoting phenotype characterized by abnormal activation
and promotion of pathologic angiogenesis. miR-150 was previously reported to play important roles in
controlling B cell differentiation by targeting the transcription factor c-Myb (28). Moreover, miR-150 has
been reported to regulate de novo lipogenesis by targeting Fasn and other lipid-related genes in mammary
epithelium (29). Here, we uncover a potentially novel role for miR-150 in macrophages to regulate cholesterol metabolism and lipid trafficking genes involved in AMD based on our RNA-Seq results. In agreement,
other miRs have been shown to regulate cholesterol homeostasis. For example, miR-33 (4, 30), miR-302a
(31), and miR-19b (32) regulate reverse cholesterol transport by modulating Abca1 expression.
Consistent with their impaired cholesterol metabolism and lipid trafficking, we report that aged macrophages with miR-150 upregulation have associated alterations in ceramide and phospholipid profiles.
These results build on our previous finding that aged macrophages have impaired cholesterol efflux (4).
Specifically, aged macrophages have a reduced ratio of very long–chain to long-chain ceramides. Ceramides are important signaling molecules in macrophages that modulate cellular responses in many pathways, including inflammation (33). Different molecular ceramide species have been shown to be significantly associated with mortality in coronary artery disease patients independently of traditional risk factors
(34), highlighting their importance in disease pathogenesis. Additionally, we demonstrate that aged macrophages have alterations in phospholipid composition in multiple classes. Of interest, both ceramides and
phospholipids are important components of the plasma membrane, and the composition and organization
of the plasma membrane have been shown to be important for modulating cholesterol-dependent signaling
networks involved in inflammation (26).
We propose that broad disruptions in plasma membrane lipids secondary to miR-150 upregulation in
aged macrophages modulate the inflammatory status of aged macrophages and thereby predispose them
toward a disease-promoting, proangiogenic phenotype. Our lipidomic analysis shows that aged macrophages possess a complex profile of altered lipid composition with remodeling toward long-chain ceramides and a shift toward phospholipids containing unsaturated fatty acids. We provide further insight by
demonstrating that 1 molecular mechanism by which miR-150 regulates lipid metabolism in macrophages
is direct targeting of Scd2. This gene catalyzes the rate-limiting step in the formation of monounsaturated
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fatty acids and has been shown to be important in lipid synthesis during early skin and liver development
(35). Our data establish that Scd2 is also evidently important in macrophage function, as Scd2-deficient macrophages exhibit abnormal activation and promote pathological angiogenesis. Although Scd2 deficiency
alone might be expected to cause accumulation of phospholipids containing saturated fatty acids in aged
macrophages, we did not observe this pattern in our lipidomic analysis, suggesting that Scd2 deficiency does
not drive alterations in lipid composition alone. We propose instead that the combination of Scd2 deficiency and changes in other lipid-related genes causes the altered lipid profile of aged macrophages.
Of translational relevance, our study provides strong evidence that miR-150 plays a role in AMD
pathogenesis. Specifically, our data indicate not only that AMD patients have higher PBMC miR-150 levels
than control participants, but also that increased PBMC miR-150 is significantly associated with increased
odds of AMD in a sex- and age-adjusted binary logistic regression model. Although miR-150 levels were
associated with disease in human PBMCs, there was no clear relationship between miR-150 levels and age,
unlike in murine macrophages, highlighting a difference between murine and human macrophages.
Overall, our findings are timely, given a recent report that showed that there is an increase in the number of choroidal macrophages in human eyes with AMD (36), strongly implicating a pathogenic role for
macrophages in disease. Moreover, our findings may partially explain why activated macrophages derived
from neovascular AMD patients have proangiogenic characteristics (37, 38). While other groups have suggested that endothelial miR-150 may suppress pathologic ocular neovascularization (39, 40), our findings
highlight a distinct, macrophage-specific role for miR-150 that, in fact, promotes pathological ocular neovascularization. These differences are not surprising, given that miRs can act in a cell-specific manner.
Ultimately, these findings open up therapeutic vistas for miR-based therapies for AMD. Moreover, understanding the mechanisms that cause macrophage aging and how such aging contributes to AMD also has
broad applicability to other age-associated diseases by educating us about critical unifying pathways that
drive their pathobiology.

Methods
Animals. We obtained 18-month-old, WT C57BL/6J mice from the National Institute on Aging and compared them with strain-matched, young (i.e., 2- to 3-month-old) WT controls. We obtained mice with floxed
Fasn alleles (Fasnf/f) (41) from Clay Semenkovich (Washington University School of Medicine) and mice
with floxed Scd2 alleles (Scd2f/f) (42, 43) from Hide Tsukamoto (Keck School of Medicine of the University
of Southern California, Los Angeles, California, USA). We crossed these floxed mice with mice carrying
the lysozyme M-Cre (LysMcre) transgene (44) to generate mice with myelomonocytic-specific deletion of
Fasn (Fasn–m/–m) and Scd2 (Scd2–m/–m). We harvested PMs, SMs, and BMDMs from female mice at the ages
indicated and used equal proportions of male and female mice for laser-injury CNV experiments. Unless
otherwise specified, we used mice that were 2–3 months of age for experimentation.
Macrophages. We harvested PMs from mice 5 days after elicitation with 4% thioglycollate (MilliporeSigma). We harvested SMs from mice by mincing spleens with a razor blade, incubating in spleen dissociation medium (Stemcell Technologies) for 30 minutes at room temperature, and performing magnetic
cell separation with the PE selection kit (Stemcell Technologies) and PE-conjugated F4/80 monoclonal
antibody (clone BM8; eBioscience), following manufacturer’s instructions. We cultured PMs and SMs in
RPMI 1640 medium (Thermo Fisher Scientific) supplemented with 10% FBS (Atlanta Biologicals) and 1%
penicillin-streptomycin (Thermo Fisher Scientific). Additionally, we generated BMDMs by culturing BM
aspirates from mice in RPMI 1640 medium (Thermo Fisher Scientific) supplemented with 20% L929-conditioned medium, 10% FBS (Atlanta Biologicals), 1% GlutaMAX (Thermo Fisher Scientific), and 1% penicillin-streptomycin (Thermo Fisher Scientific). Monocytes were allowed to differentiate for 1 week prior to
experimentation. When indicated, we treated macrophages with 25 μg/ml oxLDL (Intracel) for 24 hours,
25 μg/ml acLDL (Intracel) for 24 hours, or 100 ng/ml LPS (MilliporeSigma) for 24 hours.
miR microarray. We profiled miR expression of young and aged PMs that (i) were left untreated, (ii) were
treated with 25 μg/ml acLDL for 24 hours, or (iii) were treated with 25 μg/ml oxLDL for 24 hours (total of
6 groups; 3 treatments × 2 ages). We extracted RNA with the mirVana miRNA isolation kit (Thermo Fisher
Scientific), determining quantity and quality of the RNA with a 2100 BioAnalyzer and the Total RNA Pico kit
(Agilent Technologies). All samples (n = 24) had RNA integrity numbers (RIN) > 9.5. We labeled each sample
with FlashTag Biotin HSR RNA Labeling Kits (Affymetrix) to prepare them for the GeneChip miRNA 3.0
Array. We processed the array results with Affymetrix Expression Console (v1.3.1.187) at standard settings
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(RMA background correction, median polish summarization, and quantile normalization) to generate intensity values with a second set of data produced without quantile normalization. We filtered the data by probeset
type and by detection call and removed probesets without a “detected” call in any of the 24 samples; after this
filtering, we retained 1,093 of the initial 1,966 probesets for further statistical analysis. To identify potential
outliers, we performed principal component analysis (PCA) and hierarchical clustering and assessed quality
control (QC) metrics from Expression Console (e.g., all probeset RLE means > 0.25). This analysis identified 3
outliers, which we omitted from further analysis. We performed statistical analysis with the R package “limma”
(45) to generate lists of miRs differentially expressed in our various groups based on their P values and FDR-adjusted P values (i.e., q values). The microarray data are available at the Gene Expression Omnibus (GEO) at
NCBI under accession number GSE111323.
miR expression profiling. For miR expression profiling, we extracted total RNA with the mirVana miRNA isolation kit (Thermo Fisher Scientific) and prepared cDNA with the universal cDNA synthesis kit II
(Exiqon). We then performed qPCR using ExiLENT SYBR Green master mix (Exiqon) and miR LNA
primer sets (Exiqon). To analyze the data, we used the ΔΔCT method, normalizing to U6 expression. A list
of primers used for miR qPCR is provided in Supplemental Table 2.
mRNA expression profiling. For mRNA expression profiling, we extracted RNA with the RNeasy kit
(Qiagen) and prepared cDNA with the high-capacity cDNA reverse transcription kit (Thermo Fisher Scientific). We then performed qPCR with TaqMan fast advanced master mix (Thermo Fisher Scientific) and
TaqMan real-time PCR gene expression assays (Thermo Fisher Scientific). A list of primers used for qPCR
is provided in Supplemental Table 2. We also profiled mRNA expression with custom TaqMan array plates
(Thermo Fisher Scientific) with the assays indicated in Supplemental Table 3. We used the ΔΔCT method,
normalizing to 1 or more housekeeping gene, as appropriate.
RNA-Seq. We extracted total RNA from PMs transfected with either synthetic miR–150-5p or NC
(Exiqon) with TRIzol (Thermo Fisher Scientific), followed by column purification with the RNeasy Plus
mini kit (Qiagen). We determined the quantity and quality of the RNA samples with a 2100 BioAnalyzer
and the Total RNA Pico kit (Agilent Technologies). All samples (n = 12) had RIN > 9.6. We analyzed the
transcriptomes of PMs after miR-150 overexpression with RNA-Seq, with an initial input of 600 ng of
total RNA per sample before mRNA enrichment with the rRNA Ribo-Zero rRNA removal kit (Illumina).
We prepared sequencing libraries with standard protocols. QC revealed improper fragmentation of 1 sample, which was omitted from further analysis. The remaining samples (n = 11) were sequenced in 2 flowcell lanes on a HiSeq 2500 (Illumina) at the Washington University Genome Technology Access Center
(GTAC). We mapped the sequencing reads to the genome with Spliced Transcripts Alignment to a Reference (STAR) (https://github.com/alexdobin/STAR). Next, we performed a standard EdgeR and Sailfish
analysis of gene-level features. We defined a significant up- or downregulation as a |fold-change| > 1.20
with a FDR < 0.20. We performed pathway analysis for enrichment in GO processes, process networks,
and pathway maps with MetaCore (Clarivate Analytics). The RNA-Seq data are available at the GEO at
NCBI under accession number GSE111323.
Lipidomic analysis. We suspended macrophages in PBS at 2.0 × 106 cells/ml and performed protein
precipitation from 100 μl of macrophage suspension to extract ceramides, PCs, PEs, PIs, PGs, and PSs.
Prior to extraction, we added deuterated d5-Cer (16:0), d4-Cer (22:0), and d4-Cer (24:0) as internal standards
for ceramides and PC (28:2), PE (32:2), PG (30:0), PI (32:0), and PS (28:0) as internal standards for the
other lipid classes. We measured lipids with a Shimadzu 10A HPLC system and a Shimadzu SIL-20AC
HT auto-sampler coupled to a Thermo Scientific TSQ Quantum Ultra triple quadrupole mass spectrometer
operated in SRM mode under ESI(+). We conducted data processing with Xcalibur (Thermo Fisher Scientific). We prepared QC samples by pooling aliquots of the study samples and injected them between every
5 samples to monitor instrument performance, omitting lipid species with coefficients of variance >15% in
QC samples. We performed relative quantification by comparing the peak area ratios of the analytes to the
corresponding internal standards.
Human subjects. To isolate PBMCs, we performed density gradient centrifugation with BD Vacutainer CPT
cell preparation tubes. We stored PBMC pellets at –80°C until further analysis. We classified patients as no
AMD, early AMD, or wet AMD based on established clinical criteria (46). Early AMD patients had either
moderate drusen (>63 μm) or pigment changes in at least 1 eye but no CNV or GA in either eye at the time of
sample collection. Wet AMD patients had CNV in at least 1 eye at the time of sample collection. We excluded
patients with pattern dystrophy, macular telangiectasia, dominant drusen, or central serous chorioretinopathy.
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Absolute miR-150 quantification in human PBMCs. We extracted RNA from PBMCs with the mirVana
miRNA isolation kit (Thermo Fisher Scientific) and performed reverse transcription (RT) with the universal cDNA synthesis kit II (Exiqon) by adding 2 μl of RNA to 2 μl of 5× reaction buffer, 1 μl of enzyme
mix, and 5 μl of nuclease-free H2O (total volume, 10 μl). We diluted the cDNA to a final volume of 60 μl
and performed miRCURY LNA Universal RT miR PCR by adding 4 μl of diluted cDNA to 1 μl of the
appropriate primer and 5 μl of ExiLENT SYBR Green master mix (total volume, 10 μl). To determine
absolute copy number of human-miR-150-5p (hsa-miR-150-5p), we prepared standard curves with serial
dilutions of synthetic hsa-miR-150-5p (Integrated DNA Technologies) ranging from 1 × 104 copies per 2
μl input to 1 × 1010 copies per 2 μl input, followed by RT and PCR as above. To account for differences
in RNA extraction and RT efficiency performed on separate occasions, we spiked in 20 fmol of synthetic
C. elegans–miR-39-3p (cel-miR-39-3p) (Integrated DNA Technologies) into each sample prior to RNA
extraction and normalized to the global arithmetic mean. We normalized miR-150 copy number for each
patient by dividing by the total RNA used for RT.
miR-150 overexpression. To transiently overexpress miR-150 in PMs, we used commercially available
miRCURY LNA miR mimics (Exiqon), following standard protocols for fast-forward transfection. In
short, we plated PMs at 1 × 106 cells/well in 6-well plates. Two hours after plating, we prepared transfection complexes by combining miR mimic (20 nM) and HiPerFect transfection reagent (18 μl/well; Qiagen) in RPMI medium supplemented with 10% FBS (Atlanta Biologicals) and 1% penicillin-streptomycin
(Thermo Fisher Scientific), incubating for 15 minutes at room temperature before adding to the cells. We
assessed transfection efficiency with fluorescence microscopy by visualizing fluorescein amidite–labeled
(FAM-labeled) miR mimics.
miR-150 target identification. To identify miR-150 targets, we retrieved 3′ UTR sequences from the UCSC
Genome Brower (genome.ucsc.edu; Mouse Assembly GRCm38/mm10) and manually searched for the
presence of relevant miR-150 seed sequences (8mer site: 3′ - UUGGGAGA - 5′; 7mer-m8 site: 3′ - UUGGGAG - 5′; 7mer-A1 site: 3′ - UGGGAGA - 5′; 6mer site: 3′ - UGGGAG - 5′; offset 6mer site: 3′ - UUGGGA - 5′). Additionally, we used existing miR target identification databases: TargetScanMouse (release 7.1)
(47), DIANA-microT-CDS (version 5.0) (48), DIANA-TarBase (version 7.0) (49), miRDB (50), RNA22
(version 2.0) (51), and microRNA.org (August 2010 release) (52).
Fasn/Scd2 knockdown. To transiently knock down Fasn and Scd2, we used commercially available FlexiTube siRNA (Qiagen), following standard protocols for fast-forward transfection. In short, we plated PMs
at 1 × 106 cells/well in 6-well plates. Two hours after plating, we prepared siRNA transfection complexes
by combining siRNA (50 nM) and HiPerFect transfection reagent (18 μl/well; Qiagen) in RPMI medium
supplemented with 10% FBS (Atlanta Biologicals) and 1% penicillin-streptomycin (Thermo Fisher Scientific), incubating for 15 minutes at room temperature before adding to the cells. We confirmed efficient siRNA
knockdown by qPCR. We analyzed macrophage activation and function 48 hours after transfection.
miRNA target dual-reporter assays. We ordered custom miTarget 3′ UTR miRNA target clones from
GeneCopoeia with WT or mutated Scd2 3′ UTR inserted downstream of a secreted GLuc reporter gene
driven by the SV40 promoter and a secreted alkaline phosphatase (SEAP) reporter gene driven by a CMV
promoter. We cotransfected 293T cells (ATCC), cultured routinely in high-glucose DMEM (Thermo Fisher
Scientific) supplemented with 10% FBS (Atlanta Biologicals), with the target clone and either miR-150 mimic or nontargeting NC mimic (Exiqon), following manufacturer’s instructions. In brief, we plated 293T cells
in 96-well plates at 2 × 104 cells/well the day before transfection. On the day of transfection, we prepared
transfection complexes by combining the target clone (100 ng/well), miR mimic (20 nM), Lipofectamine
3000 (0.15 μl/well; Thermo Fisher Scientific), and P3000 reagent (0.20 μl/well) in Opti-MEM medium
(Thermo Fisher Scientific) and incubating for 30 minutes at room temperature before adding to the cells.
Forty-eight hours after transfection, we collected the supernatant to measure GLuc activity with the Secrete
Pair Dual Luminescence assay kit (GeneCopoeia). We normalized for transfection efficiency by measuring
SEAP activity. We optimized cotransfection conditions with a positive-control pmaxGFP plasmid (Lonza).
CNV experiments. We performed laser-induced CNV as described previously (53). Briefly, we anesthetized
mice and placed 4 laser spots around the optic disc (200 mW, 0.1 second, 100 μm spot size) using a slit-lamp
delivery system with a cover glass as a contact lens. Seven days after injury, we perfused the mice with 2,000
μl of 5 mg/ml FITC-dextran (molecular weight, 2,000,000 daltons; MilliporeSigma) through the left ventricle.
We then enucleated the eyes and fixed them in 2% paraformaldehyde (PFA; Alfa Aesar) for 30 minutes. After
fixation, we washed the eyes with PBS and flat-mounted the retinal pigment epithelium–choroid (RPE-choroid)
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complex onto a glass slide. We acquired Z-stack images of the CNV spots using an Olympus FV1000 confocal
microscope and processed images with ImageJ (NIH) to generate pseudo-volumetric 2-dimensional images.
After excluding laser spots that resulted in retinal, subretinal, or vitreous hemorrhage, we quantified pixel intensity using MetaMorph (Molecular Devices). For immunotherapy experiments, we adoptively transferred 100,000
macrophages into each eye in 2 μl PBS immediately following laser injury via intravitreal injection with a 10 μl
Neuros Model 1701 RN syringe (point style 4) and small-hub, 31-gauge needles (Hamilton).
VEGF measurements. We measured VEGF secretion in supernatants from macrophages with the mouse
VEGF Quantikine ELISA kit (R&D Systems), following manufacturer’s instructions.
Statistics. We performed statistical analysis with Prism 5 (Graphpad) or SPSS Statistics (Version 23;
IBM). We assessed the normality of our data graphically and with the Kolmogorov-Smirnov test, using
nonparametric alternatives when appropriate. When comparing a single variable between 2 groups, we used
2-tailed t tests or 2-tailed Mann-Whitney U tests. For other analyses, we performed the appropriate statistical
test for each type of data, as indicated in figure legends. A P value less than 0.05 was considered significant.
Open circles depict individual data points or individual human subjects. Box-and-whisker plots depict medians, with boxes outlining the interquartile range and whiskers indicating the minima and maxima.
We performed an a priori power calculation with G*Power 3.1 (54) to determine the appropriate sample
size for our human studies. To detect a significant difference between AMD patients and control subjects
(allocation ratio: 1.0:1.5) at the 2-sided α = 0.05 level with an estimated effect size d of 0.6 based on pilot
experiments and 80% power, we calculated that we needed to recruit 94 subjects total. We exceeded this
threshold (n = 106), yielding adequate statistical power to detect our anticipated difference. To model the
relationship between PBMC miR-150 levels and AMD, we generated a binary logistic regression model.
Our model included the predictor variables of age at the time of sample collection, sex, and log10-transformed PBMC miR-150 levels. We assessed model fit with the Hosmer-Lemeshow lack-of-fit test and
performed model diagnostics by examining Cook’s distances, leverages, and residual deviances. No cases
were omitted upon sensitivity analysis. We checked for collinearity by examining variance inflation factors
(VIF). We used an unadjusted α of 0.05 for the binary logistic regression.
Study approval. All animal experiments were reviewed and approved by the IACUC of Washington
University in St. Louis and performed in accordance with the Washington University School of Medicine
Animal Care and Use guidelines. The human study was reviewed and approved by the Human Research
Protection Office of Washington University in St. Louis and adhered to the Declaration of Helsinki. We
obtained informed consent from all human subjects prior to blood collection.
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